ME01901B - Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja - Google Patents

Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja

Info

Publication number
ME01901B
ME01901B MEP-2014-91A MEP9114A ME01901B ME 01901 B ME01901 B ME 01901B ME P9114 A MEP9114 A ME P9114A ME 01901 B ME01901 B ME 01901B
Authority
ME
Montenegro
Prior art keywords
roflumilast
pharmaceutically acceptable
hmg
acceptable salt
coa reductase
Prior art date
Application number
MEP-2014-91A
Other languages
English (en)
Inventor
Stefan-Lutz Wollin
Andrea Wohlsen
Clemens Braun
Degenhard Marx
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME01901B publication Critical patent/ME01901B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (56)

1.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i najmanje jednu farmaceutski prihvatljivu pomoćnu supstancu, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N- oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so, i pri čemu prva količina i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja.
2.Proizvod kombinacije koji sadrži komponente: (A) količinu PDE4 inhibitora; (B) količinu inhibitora HMGCoA reduktaze; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja i pri čemu svaka od komponenti (A) i (B) je formulisana u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
3.Oprema koja sadrži komponente: (A) farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; (B) farmaceutsku formulaciju koja obuhvata količinu inhibitora HMG-CoA reduktaze, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
4.Farmaceutska kompozicija prema zahtevu 1, pri čemu PDE4 inhibitor je ROFLUMILAST.
5.Farmaceutska kompozicija prema zahtevu 1, pri čemu PDE4 inhibitor je ROFLUMILAST- N-oksid.
6.Farmaceutska kompozicija prema bilo kom od zahteva 1,4 ili 5, pri čemu inhibiot HMG- CoA reduktaze je SIMVASTATIN.
7. Proizvod kombinacije prema zahtevu 2, pri čemu PDE4 inhibitor je ROFLUMILAST.
8. Proizvod kombinacije prema zahtevu 2, pri čemu PDE4 inhibitor je ROFLUMILAST-N- oksid.
9.Proizvod kombinacije prema bilo kom od zahteva 2, 7 i 8, pri čemu inhibitor HMG-CoA reduktaze je SIMVASTATIN.
10. Oprema prema zahtevu 3, pri čemu PDE4 inhibitor je ROFLUMILAST.
11. Oprema prema zahtevu 3, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
12.Oprema prema bilo kom od zahteva 3, 10 ili 11, pri čemu inhibitor HMG-CoA reduktaze je SIMVASTATIN.
13.Farmaceutska kompozicija prema bilo kom od zahteva 1,4, 5 ili 6, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
14.Farmaceutska kompozicija prema bilo kom od zahteva 1,4, 5 ili 6, gde je inflamatorno pulmonarno oboljenje COPD.
15.Proizvod kombinacije prema bilo kom od zahteva 2, 7, 8 ili 9, gdeje inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
16.Proizvod kombinacije prema bilo kom od zahteva 2, 7, 8 or 9, gde je inflamatorno pulmonarno oboljenje COPD.
17.Oprema prema bilo kom od zahteva 3, 10, 11 ili 12, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
18.Oprema prema bilo kom od zahteva 3, 10, 11 ili 12, gdeje inflamatorno pulmonarno oboljenje COPD.
19.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju medikamenta, prvenstveno farmaceutske kompozicije prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
20.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju sekvencijalnog ili odvojenog medikamenta za istovremenu primenu, prvenstveno proizvoda kombinacije ili opreme prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
21.Primena prema bilo kom od zahteva 19 ili 20, pri čemu PDE4 inhibitor je ROFLUMILAST.
22.Primena prema bilo kom od zahteva 19 ili 20, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
23.Primena prema bilo kom od zahteva 19, 20, 21 ili 22, pri čemu inhbitor HMG-CoA reduktaze je SIMVASTATIN.
24.Primena prema bilo kom od zahteva 19 do 23, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
25.Primena prema bilo kom od zahteva 19 do 23, gde je inflamatorno pulmonarno oboljenje COPD.
26.Postupak za dobijanje farmaceutske kompozicije kao što je definisano u bilo kom od zahteva 1,4, 5, 6, 13 ili 14, koji obuhvata mešanje PDE4 inhibitora ili njegove farmaceutski prihvatljive soli sa inhibitorom HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli.
27.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i najmanje jednu farmaceutski prihvatljivu pomoćnu supstancu, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N- oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so, i pri čemu prva količina i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja.
28.Proizvod kombinacije koji sadrži komponente: (A) količinu PDE4 inhibitora; (B) količinu inhibitora HMGCoA reduktaze; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja i pri čemu svaka od komponenti (A) i (B) je formulisana u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so.
29.Oprema koja sadrži komponente: (A) farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; (B) farmaceutsku formulaciju koja obuhvata količinu inhibitora HMG-CoA reduktaze, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog obolenja, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so.
30.Farmaceutska kompozicija prema zahtevu 27, pri čemu PDE4 inhibitor je ROFLUMILAST.
31.Farmaceutska kompozicija prema zahtevu 27, pri čemu PDE4 inhibitor je ROFLUMILASTN-oxide.
32.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30 ili 31, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
33.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30 ili 31, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
34.Proizvod kombinacije prema zahtevu 28, pri čemu PDE4 inhibitor je ROFLUMILAST.
35.Proizvod kombinacije prema zahtevu 28, pri čemu PDE4 inhibitor je ROFLUMILAST-N- oksid.
36.Proizvod kombinacije prema bilo kom od zahteva 28, 34 i 35, pri čemu inhibitor HMG- CoA reduktaze je ATORVASTATIN.
37.Proizvod kombinacije prema bilo kom od zahteva 28, 34 i 35, pri čemu inhibitor HMG- CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
38.Oprema prema zahtevu 29, pri čemu PDE4 inhibitor je ROFLUMILAST.
39.Oprema prema zahtevu 29, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
40.Oprema prema bilo kom od zahteva 29, 38 ili 39, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
41.Oprema prema bilo kom od zahteva 29, 38 ili 39, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemikalcijum seks-hidrat.
42.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30, 31, 32 ili 33, gdeje inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
43.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30, 31, 32 ili 33, gde je inflamatorno pulmonarno oboljenje COPD.
44.Proizvod kombinacije prema bilo kom od zahteva 28, 34, 35, 36 ili 37, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
45.Proizvod kombinacije prema bilo kom od zahteva 28, 34, 35, 36 ili 37, gde je inflamatorno pulmonarno oboljenje COPD.
46.Oprema prema bilo kom od zahteva 29, 38, 39, 40 ili 41, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmoname hipertenzije.
47.Oprema prema bilo kom od zahteva 29, 38, 39, 40 ili 41, gde je inflamatorno pulmonarno oboljenje COPD.
48.Primena PDE4 inhibitor ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju medikamenta, prvenstveno farmaceutske kompozicije prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutska prihvatljiva so.
49.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju sekvencijalnog ili odvojenog medikamenta za istovremenu primenu, prvenstveno proizvoda kombinacije ili opreme prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutska prihvatljiva so.
50.Primena prema bilo kom od zahteva 48 ili 49, pri čemu PDE4 inhibitor je ROFLUMILAST.
51.Primena prema bilo kom od zahteva 48 ili 49, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
52.Primena prema bilo kom od zahteva 48, 49, 50 ili 51, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
53.Primena prema bilo kom od zahteva 48, 49, 50 ili 51, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
54.Primena prema bilo kom od zahteva 48 do 53, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
55.Primena prema bilo kom od zahteva 48 do 53, gde je inflamatorno pulmonamo oboljenje COPD.
56.Postupak za dobijanje farmaceutske kompozicije kao što je definisano u bilo kom od zahteva 27, 30, 31,32, 33, 42 ili 43, koji obuhvata mešanje PDE4 inhibitora ili njegove farmaceutski prihvatljive soli sa inhibitorom HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli.
MEP-2014-91A 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja ME01901B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116625 2006-07-05
EP11164518.0A EP2363130B1 (en) 2006-07-05 2007-07-03 Combination of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases

Publications (1)

Publication Number Publication Date
ME01901B true ME01901B (me) 2014-12-20

Family

ID=37311957

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2014-91A ME01901B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
MEP-2014-9A ME01648B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2014-9A ME01648B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja

Country Status (26)

Country Link
US (2) US20100069392A1 (me)
EP (3) EP2359826B1 (me)
JP (3) JP5349302B2 (me)
KR (1) KR101433394B1 (me)
CN (3) CN102764440A (me)
AT (1) ATE535244T1 (me)
AU (1) AU2007271186C1 (me)
BR (1) BRPI0713768A2 (me)
CA (1) CA2656366A1 (me)
CY (2) CY1114742T1 (me)
DK (2) DK2359826T3 (me)
EA (2) EA032476B1 (me)
ES (3) ES2443342T3 (me)
HR (2) HRP20140073T1 (me)
IL (3) IL195433A (me)
ME (2) ME01901B (me)
MX (1) MX2008016123A (me)
NO (1) NO342590B1 (me)
NZ (3) NZ594369A (me)
PL (2) PL2363130T3 (me)
PT (2) PT2359826E (me)
RS (2) RS53084B (me)
SI (2) SI2363130T1 (me)
UA (3) UA98466C2 (me)
WO (1) WO2008003701A2 (me)
ZA (1) ZA200809905B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463084A (zh) * 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
US10526656B2 (en) 2014-06-05 2020-01-07 Transgenion—International Institute for Regenerative Translational Medicine GmbH Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
EP3152329A2 (en) * 2014-06-05 2017-04-12 Transregion-International Institute For Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
EP3152330B1 (en) * 2014-06-05 2021-01-27 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途
WO2024028388A1 (en) * 2022-08-03 2024-02-08 Chiesi Farmaceutici S.P.A. Dry powder inhaler

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU535944B2 (en) 1979-06-15 1984-04-12 Merck & Co., Inc. Hypocholestermic fermentation products from aspergillus
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
PT87929B (pt) 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
DK0513387T3 (da) 1990-11-30 2000-06-05 Otsuka Pharma Co Ltd Thiazolderivater som inhibitorer af aktivt oxygen
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
ATE200980T1 (de) * 1992-04-02 2001-05-15 Smithkline Beecham Corp Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
MX9709897A (es) 1995-06-06 1998-03-31 Pfizer 5-6-dihidro-9h-pirazol[3,4-c]-1,2,4-triazol[4,3-a]piridinas triciclicas y el uso de las mismas.
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DK1076657T3 (da) 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE19944161A1 (de) 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US20030018040A1 (en) 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
JP2001294526A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd ＴＮＦ−α抑制剤
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US20050102317A1 (en) * 2000-07-21 2005-05-12 Ali Kamarei System and method for event calendaring using a customizable rules subset
JP2004512278A (ja) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤）
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
NZ527424A (en) 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
JP4193435B2 (ja) * 2002-07-23 2008-12-10 ブラザー工業株式会社 インクカートリッジ、および、そのインク充填方法
ATE303384T1 (de) * 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
EP1404330B1 (en) * 2001-06-27 2005-06-01 Merck Frosst Canada & Co. Substituted 8-arylquinoline pde4 inhibitors
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
CA2506442A1 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
DK1567139T3 (da) * 2002-11-27 2008-11-03 Nycomed Gmbh Hidtil ukendt synergistisk kombination der omfatter roflumilast og formoterol
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
SI1620429T1 (sl) 2003-04-11 2009-08-31 Glenmark Pharmaceuticals Sa Nove heterociklične spojine, uporabne za zdravljenje vnetnih in alergijskih motenj: postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
CA2523336A1 (en) * 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
DE10348646A1 (de) 2003-10-15 2005-05-25 Gkn Driveline International Gmbh Rollbalg mit großem Krümmungsradius
WO2005102348A1 (en) * 2004-04-19 2005-11-03 Loma Linda University Composition and method of decreasing renal ischemic damage
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
GB0508924D0 (en) 2005-04-30 2005-06-08 Astrazeneca Ab New use
GB0510207D0 (en) 2005-05-19 2005-06-22 Astrazeneca Ab Novel combination
PT1894576E (pt) 2005-06-08 2011-07-29 Kowa Co Novo agente redutor dos níveis de triglicéridos
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis

Also Published As

Publication number Publication date
EA200900073A1 (ru) 2009-06-30
IL195433A (en) 2013-02-28
US20100069392A1 (en) 2010-03-18
KR101433394B1 (ko) 2014-08-26
JP5349302B2 (ja) 2013-11-20
PT2359826E (pt) 2014-01-20
RS53084B (sr) 2014-06-30
EP2359826A1 (en) 2011-08-24
JP2013035871A (ja) 2013-02-21
DK2359826T3 (da) 2014-01-20
PL2359826T3 (pl) 2014-04-30
AU2007271186B2 (en) 2013-01-17
UA98466C2 (uk) 2012-05-25
CN101484166B (zh) 2012-09-05
KR20090025368A (ko) 2009-03-10
ES2443342T3 (es) 2014-02-19
AU2007271186C1 (en) 2013-08-15
NO20090370L (no) 2009-02-04
NZ603207A (en) 2013-12-20
SI2359826T1 (sl) 2014-02-28
IL195433A0 (en) 2009-08-03
JP2009541459A (ja) 2009-11-26
NZ573378A (en) 2012-03-30
IL221307A0 (en) 2012-09-24
IL221309A (en) 2014-12-31
EA032476B1 (ru) 2019-06-28
EA201401042A1 (ru) 2016-05-31
CN101484166A (zh) 2009-07-15
NO342590B1 (no) 2018-06-18
SI2363130T1 (sl) 2014-09-30
CA2656366A1 (en) 2008-01-10
AU2007271186A1 (en) 2008-01-10
JP2013035870A (ja) 2013-02-21
EP2040707A2 (en) 2009-04-01
UA106422C2 (uk) 2014-08-26
UA101556C2 (uk) 2013-04-10
PL2363130T3 (pl) 2014-09-30
EP2363130A1 (en) 2011-09-07
ES2489265T3 (es) 2014-09-01
EP2363130B1 (en) 2014-05-07
ZA200809905B (en) 2009-11-25
NZ594369A (en) 2013-10-25
ATE535244T1 (de) 2011-12-15
DK2363130T3 (da) 2014-07-21
ES2378281T3 (es) 2012-04-10
CN102764440A (zh) 2012-11-07
CN102772411A (zh) 2012-11-14
PT2363130E (pt) 2014-06-25
WO2008003701A3 (en) 2008-03-13
US9713614B2 (en) 2017-07-25
HRP20140707T1 (hr) 2014-09-12
BRPI0713768A2 (pt) 2012-10-30
WO2008003701A2 (en) 2008-01-10
EA021461B1 (ru) 2015-06-30
ME01648B (me) 2014-09-20
EP2040707B1 (en) 2011-11-30
US20150272949A1 (en) 2015-10-01
RS53461B (sr) 2014-12-31
IL221307A (en) 2014-08-31
CY1115462T1 (el) 2017-01-04
EP2359826B1 (en) 2013-10-30
CY1114742T1 (el) 2016-12-14
HRP20140073T1 (hr) 2014-02-28
MX2008016123A (es) 2009-01-15

Similar Documents

Publication Publication Date Title
ME01648B (me) Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008063300A3 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
PH12018502522A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2008011117A3 (en) Antiviral protease inhibitors
EA201201496A1 (ru) Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
WO2024155965A3 (en) Biomarkers for use in integrin inhibitor therapy
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
HRP20110023T1 (hr) Smanjenje prekomjerne težine ili pretilosti
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
WO2006129237A3 (en) Novel piperidine carboxylic acid amide derivatives
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2008153374A8 (es) Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
EP2323655A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT
BRPI0507492A (pt) formulações de microemulsão compreendendo antagonistas de substáncia p
HRP20170267T1 (hr) Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.